EIS-12656 (ALC1 Inhibitor)
HRD cancers (e.g., breast, ovarian)
Phase 1/2Active
Key Facts
About Eisbach Bio
Eisbach Bio is pioneering a novel approach to precision oncology by targeting allosteric regulatory sites on molecular machines essential for tumor genome reorganization. Its core technology, the ALLOS platform, uses physiological screening and proprietary AI models to design highly selective small molecules that exploit synthetic lethal vulnerabilities in genetically defined cancers. The company is advancing a clinical-stage program targeting ALC1 in HRD cancers and has a preclinical pipeline targeting CHD1 and WRN, aiming to create therapies with a wider therapeutic window.
View full company profile